Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Do you offer consolidation durvalumab in a patient who had pneumonitis requiring steroids following chemoradiation for LS-SCLC?
Related Questions
Can symptomatic radiation pneumonitis ever improve spontaneously without corticosteroids?
Would you treat a patient with an N2 ipsilateral recurrence following re-resection of bronchial stump recurrence?
What is the recommendation for persistent PET uptake and elevated catecholamines at 4 months following subtotal resection and adjuvant radiation for a thoracic secretory paraganglioma?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
Do you use an LAD constraint in the setting of BID thoracic radiation for SCLC?
Do more fractionated regimens reduce severe toxicity over SBRT in patients with ILD and early-stage NSCLC?
How do you approach the treatment of LS-SCLC after SBRT for a prior NSCLC in the ipsilateral lung?
What target expansions do you use when treating with 60 Gy in 15 fractions for the lung?
For locally advanced NSCLC, does endobronchial tumor debulking just prior to treatment influence your decision making regarding bronchial tissue constraints/expected toxicity?
